Pfizer Inc. (PFE)

37.36
0.30 0.80
NYSE : Health Technology
Prev Close 37.66
Open 37.45
Day Low/High 37.31 / 37.60
52 Wk Low/High 32.32 / 39.43
Volume 15.55M
Avg Volume 19.83M
Exchange NYSE
Shares Outstanding 5.85B
Market Cap 220.24B
EPS 3.60
P/E Ratio 10.46
Div & Yield 1.36 (3.53%)

Latest News

Be Alert For Buying Opportunities: Cramer's 'Mad Money' Recap (Monday 7/16/18)

Be Alert For Buying Opportunities: Cramer's 'Mad Money' Recap (Monday 7/16/18)

Jim Cramer says this market is all about being opportunistic, about being willing to fight the tide.

Four Great, Conservative Income Stocks

From Coca-Cola to Pfizer, these blue chips offer well-supported dividend payouts.

Jim Cramer: Sometimes You Just Have to Go Against the Grain

Jim Cramer: Sometimes You Just Have to Go Against the Grain

This market is all about being opportunistic.

Pfizer Initiates Pivotal Phase 3 Program For Investigational Hemophilia B Gene Therapy

Pfizer Initiates Pivotal Phase 3 Program For Investigational Hemophilia B Gene Therapy

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study ( NCT03587116) to evaluate the efficacy and safety of current factor IX prophylaxis replacement therapy in...

U.S. FDA Approves XTANDI® (enzalutamide) For The Treatment Of Men With Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

U.S. FDA Approves XTANDI® (enzalutamide) For The Treatment Of Men With Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.

U.S. FDA Approves XTANDI® (enzalutamide) For The Treatment Of Men With Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

U.S. FDA Approves XTANDI® (enzalutamide) For The Treatment Of Men With Non-Metastatic Castration-Resistant Prostate Cancer (CRPC)

First and Only Oral Treatment FDA-Approved for Both Non-Metastatic and Metastatic CRPC

Pfizer Becomes #7 Most Shorted Dow Stock, Replacing Chevron

Pfizer Becomes #7 Most Shorted Dow Stock, Replacing Chevron

The most recent short interest data has been released for the 06/29/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Elliott Tackles AC Milan After Chinese Investors Falter; Pfizer Eyes Reorg-ICYMI

Elliott Tackles AC Milan After Chinese Investors Falter; Pfizer Eyes Reorg-ICYMI

Here's what you need to know now for Wednesday, July 11.

REPLAY: Jim Cramer on Tariffs, Oil Prices and Pfizer's Reorganization

REPLAY: Jim Cramer on Tariffs, Oil Prices and Pfizer's Reorganization

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks from the floor of the New York Stock Exchange.

Pfizer's China Exposure Could Dampen Its Reshuffle Hopes

Pfizer's China Exposure Could Dampen Its Reshuffle Hopes

For Pfizer, China is third largest market and a growing area of concern.

Pfizer: Why This Blue-Chip Dividend Stock Is a Buy Today

Pfizer: Why This Blue-Chip Dividend Stock Is a Buy Today

We believe the company has double-digit total return potential at its current price.

Dow Slumps on Trump Trade War Escalation

Dow Slumps on Trump Trade War Escalation

The Dow tumbled Wednesday, losing ground for the first session in five, after the U.S. threatened additional tariffs on $200 billion worth of China-made goods.

Pfizer Reorganization Could Set the Stage for Full-Blown Spinoff

Pfizer Reorganization Could Set the Stage for Full-Blown Spinoff

Pfizer reorganization could pave way for the company to spin off businesses.

Jim Cramer Reacts to Pfizer's Reorganization

Jim Cramer Reacts to Pfizer's Reorganization

Pfizer announced plans Wednesday to reorganize into three units.

Pfizer Doesn't Look Fundamentally or Technically Strong

Pfizer Doesn't Look Fundamentally or Technically Strong

The stock faces a lot of headwinds on a day when markets are trying to surmount trade-war woes.

Pfizer Announces Big Reorganization As It Continues Trying to Sell Consumer Biz

Pfizer Announces Big Reorganization As It Continues Trying to Sell Consumer Biz

The changes will take effect at the start of 2019.

Jim Cramer: The Money Isn't Leaving the Casino

Jim Cramer: The Money Isn't Leaving the Casino

The bets are coming off one table and going to another amid the tariff news, much to the consternation of the sideliners.

China Tariffs, Fox-Sky, Pfizer, Apple, Free Slurpees - 5 Things You Must Know

China Tariffs, Fox-Sky, Pfizer, Apple, Free Slurpees - 5 Things You Must Know

U.S. stock futures fall sharply on Wednesday, after the White House publishes a list of $200 billion worth of China-made goods it says will be hit with fresh tariffs; Twenty-First Century Fox increases its bid to buy Britain's Sky; Pfizer to 'defer' raising drug prices following talks with Donald Trump.

Pfizer Rolls Back Drug Price Hike Following Trump Talks

Pfizer Rolls Back Drug Price Hike Following Trump Talks

Pfizer bowed to pressure from President Donald Trump late Tuesday by agreeing to temporarily rollback a planned price increase following Tweets suggesting the group "should be ashamed".

Trump's Latest $200 Billion Tariff Threat and 4 Other Stories to Watch Wednesday

Trump's Latest $200 Billion Tariff Threat and 4 Other Stories to Watch Wednesday

Here are the business stories you must know as U.S. stock futures fall sharply.

Pfizer To Organize For Future Growth

Pfizer To Organize For Future Growth

Pfizer Inc. (NYSE:PFE) today announced it will organize the company into three businesses: a science-based Innovative Medicines business which will now include biosimilars and a new hospital business unit for anti-infectives and sterile injectables; an...

Pfizer's Announces It Will Defer Company's Price Increases

Pfizer's Announces It Will Defer Company's Price Increases

Following an extensive discussion with President Trump today, Pfizer's Chairman and CEO Ian Read announced that it will defer the company's price increases that were effective on July 1 to give the president an opportunity to work on his blueprint to...

Trump Blasts Pfizer for High Drug Prices in Tweet, but Stock Still Rises

Trump Blasts Pfizer for High Drug Prices in Tweet, but Stock Still Rises

President Trump criticized Pfizer and others in a tweet on July 9, saying they hiked prices 'for no reason.'

How to Play Pfizer's Fresh Upside Breakout

How to Play Pfizer's Fresh Upside Breakout

A bullish strategy for traders of PFE stock.

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient

The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.

Pfizer Hikes Drug Prices Again, Despite President Trump's Promises

Pfizer Hikes Drug Prices Again, Despite President Trump's Promises

While President Trump pledged last month that pharma companies would decide to voluntarily aggress to 'massive' drops in drug prices, clearly nobody told Pfizer.

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Monday 7/2/18)

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap (Monday 7/2/18)

Why study charts? Because they're like footprints at the scene of the crime, clues to what the big money managers are likely thinking, Jim Cramer says.

XELJANZ® (tofacitinib Citrate) Receives Marketing Authorisation In The European Union For Active Psoriatic Arthritis

XELJANZ® (tofacitinib Citrate) Receives Marketing Authorisation In The European Union For Active Psoriatic Arthritis

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who...

TheStreet Quant Rating: B+ (Buy)